Literature DB >> 7733659

The effects of cytochrome b5, NADPH-P450 reductase, and lipid on the rate of 6 beta-hydroxylation of testosterone as catalyzed by a human P450 3A4 fusion protein.

M S Shet1, K M Faulkner, P L Holmans, C W Fisher, R W Estabrook.   

Abstract

The recombinant fusion protein containing the heme domain of human P450 3A4 and the flavin domains of rat NADPH-cytochrome P450 (P450) reductase (rF450[mHum3A4/mRatOR]L1) requires both phospholipid and detergent as well as cytochrome b5 (b5) for the NADPH-dependent catalysis of the 6 beta-hydroxylation of testosterone. NADPH oxidation results in the formation of hydrogen peroxide in the presence or absence of phospholipid and detergent. NADPH oxidation and hydrogen peroxide formation are inhibited by the addition of b5 and stimulated greater than 3-fold by the addition of testosterone. Marked differences in the ability of various phospholipids to support the P450-dependent 6 beta-hydroxylation of testosterone by the fusion protein were seen. Addition of a 4-fold excess of purified NADPH-P450 reductase, in the presence of phospholipid, detergent, and b5, stimulates the rate of testosterone 6 beta-hydroxylation approximately 10-fold, providing turnover rates as high as 80 min-1 for P450 3A4. Approximately 30% of the rate of hydrogen peroxide formation is not sensitive to inhibition by the P450 inhibitor ketoconazole, suggesting hydrogen peroxide (or superoxide anion) formation directly from the reduced flavin domains of the fusion protein. It is proposed that the stimulation of NADPH oxidation observed following the addition of testosterone to the fusion protein may serve as a useful means of monitoring the interaction of other substrates with this P450 and thereby permit the rapid screening of chemicals to evaluate their potential metabolism by a human P450.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7733659     DOI: 10.1006/abbi.1995.1235

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  5 in total

1.  Defining the in Vivo Role for cytochrome b5 in cytochrome P450 function through the conditional hepatic deletion of microsomal cytochrome b5.

Authors:  Robert D Finn; Lesley A McLaughlin; Sebastien Ronseaux; Ian Rosewell; J Brian Houston; Colin J Henderson; C Roland Wolf
Journal:  J Biol Chem       Date:  2008-09-19       Impact factor: 5.157

2.  Electrocatalytically driven omega-hydroxylation of fatty acids using cytochrome P450 4A1.

Authors:  K M Faulkner; M S Shet; C W Fisher; R W Estabrook
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

Review 3.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

4.  Engineering human cytochrome P450 enzymes into catalytically self-sufficient chimeras using molecular Lego.

Authors:  Vikash Rajnikant Dodhia; Andrea Fantuzzi; Gianfranco Gilardi
Journal:  J Biol Inorg Chem       Date:  2006-07-22       Impact factor: 3.358

Review 5.  Confounding factors and genetic polymorphism in the evaluation of individual steroid profiling.

Authors:  Tiia Kuuranne; Martial Saugy; Norbert Baume
Journal:  Br J Sports Med       Date:  2014-05       Impact factor: 13.800

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.